CD274 and neoplasm: On the basis of results from CheckMate 648, nivolumab plus chemotherapy and nivolumab plus ipilimumab are now approved as new first‐line standard treatments for patients with advanced ESCC in many countries and regions including in the United States, and Japan, and in some cases specifically for use in patients with tumor cell PD‐L1 ≥1%, such as in the European Union.17, 18, 19, 20